key: cord-0846078-5c8ik5zo
authors: Karim, Salim S Abdool
title: Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
date: 2021-03-23
journal: Lancet
DOI: 10.1016/s0140-6736(21)00468-2
sha: 1f31f2f698cb0b3c4a0ebb81a630f4cf63ced92e
doc_id: 846078
cord_uid: 5c8ik5zo

nan

and reductions in neutralising activity in vaccinee serum samples for all four vaccines tested. [4] [5] [6] [7] Although these reductions were small for the BBIBP-CorV, 4 BNT162b2, 5 and mRNA-1273 6 vaccines, preliminary data suggest they were substantial, including with a complete immune escape for the AZD1222 vaccine. 7 Concerningly, the clinical trial efficacy of AZD1222 was 70% in the UK and Brazil, 8 but 22% according to preliminary data from South Africa. 7 For NVX-CoV237 the efficacy was 89% in the UK but 49% in South Africa, 9 whereas for Ad26.COV2-S the efficacy was 72% in the USA but 57% in South Africa. 10 Extrapolating vaccine efficacy against pre-existing variants to new variants could be seriously misleading.

Adequate genomic surveillance, standardised variant nomenclature, and a repository of variants and vaccinee serum samples 11 are needed to deal with the challenges of repeatedly emerging new SARS-CoV-2 variants, but there is a particularly pressing need to establish a correlate of protection so that vaccine efficacy results obtained with pre-existing variants can be translated to newly emerging variants because it is impractical and time consuming to repeat clinical trials with each new immune-escape variant. Furthermore, repeating clinical trials for each variant might take so long that even newer variants could emerge while these clinical trials are underway.

Because the immune responses required to prevent mild disease might be different to severe disease, correlates of protection might need to be stratified on the basis of disease severity. There are four key requirements to achieve this aim. First, all SARS-CoV-2 vaccine developers with existing or completed efficacy trials should commit to transparency and open data sharing. Second, an expert committee (preferably under WHO) should be appointed to review existing and planned analyses to identify correlates of protection for each efficacious vaccine. Third, studies with multiple vaccines to fast-track the identification of an animal model, assay, or marker as a correlate of protection should be initiated to address gaps in the correlate research plans. Finally, a central database should be created to collate data for each of the efficacious vaccines, thereby providing larger sample sizes to assess multiple variables as correlates of protection and to test if a correlate identified in one trial is valid in other trials.

The identification of a correlate of protection is too important and urgent to be left to uncoordinated separate studies by individual investigators or vaccine developers. South Africa, at the forefront of dealing with the challenge of its vaccine roll-out during the spread of a predominant 501Y.V2 variant, has to make vaccine decisions without adequate efficacy data. A correlate of protection for mild and severe SARS-CoV-2 infection will go a long way to providing an evidence base for these decisions and overcome the obstacles that new variants are placing on the vision of global SARS-CoV-2 control with the widespread implementation of effective immunisation. SSAK is the co-chair of the South African Ministerial Advisory Committee for COVID-19.

Centre for the AIDS Programme of Research in South Africa, Durban 4013, South Africa; Department of Epidemiology, Columbia University, New York, USA

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccine against the B.1.351 variant in South Africa

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Press release: Novavax COVID-19 vaccine demonstrates 89·3% efficacy in UK phase 3 trial

Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial

SARS-CoV-2 variants and ending the COVID-19 pandemic